MA33747B1 - Anticorps monoclonaux diriges contre la progastrine et leurs utilisations - Google Patents

Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Info

Publication number
MA33747B1
MA33747B1 MA34864A MA34864A MA33747B1 MA 33747 B1 MA33747 B1 MA 33747B1 MA 34864 A MA34864 A MA 34864A MA 34864 A MA34864 A MA 34864A MA 33747 B1 MA33747 B1 MA 33747B1
Authority
MA
Morocco
Prior art keywords
monoclonal antibodies
antibodies against
methods
progastrin
gastrin
Prior art date
Application number
MA34864A
Other languages
Arabic (ar)
English (en)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric Hollande
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Biorealites
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33747(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Biorealites filed Critical Inst Nat Sante Rech Med
Publication of MA33747B1 publication Critical patent/MA33747B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/595Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux contre la progastrine, des fragments de ceux-ci, des compositions comprenant les anticorps monoclonaux contre la progastrine, et des procédés de fabrication et d'utilisation d'anticorps monoclonaux contre la progastrine ainsi que des compositions les contenant. La présente invention concerne des procédés de traitement du cancer colorectal avec des anticorps monoclonaux contre la progastrine et des compositions comprenant des anticorps monoclonaux contre la progastrine ou des fragments de ceux-ci. La présente invention concerne en outre des procédés comprenant la détection de la progastrine, y compris des procédés de diagnostic du cancer colorectal et des procédés de surveillance de l'efficacité d'une thérapie anticancéreuse chez des sujets souffrant du cancer colorectal.
MA34864A 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations MA33747B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (fr) 2009-10-16 2010-10-15 Anticorps monoclonaux contre la progastrine et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33747B1 true MA33747B1 (fr) 2012-11-01

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34864A MA33747B1 (fr) 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Country Status (41)

Country Link
US (7) US9611320B2 (fr)
EP (2) EP2488551B1 (fr)
JP (3) JP5985987B2 (fr)
KR (2) KR20120091221A (fr)
CN (2) CN102791735B (fr)
AP (1) AP2012006262A0 (fr)
AR (1) AR078659A1 (fr)
AU (1) AU2010306119A1 (fr)
BR (1) BR112012008818B1 (fr)
CA (1) CA2777691C (fr)
CL (1) CL2012000914A1 (fr)
CR (1) CR20120184A (fr)
CU (1) CU24196B1 (fr)
CY (1) CY1120913T1 (fr)
DK (1) DK2488551T3 (fr)
EA (2) EA029271B1 (fr)
EC (1) ECSP12011796A (fr)
ES (2) ES2973217T3 (fr)
GE (1) GEP201706604B (fr)
GT (1) GT201200114A (fr)
HK (1) HK1178183A1 (fr)
HN (1) HN2012000708A (fr)
HR (1) HRP20181645T1 (fr)
IL (2) IL219019B (fr)
IN (1) IN2012DN03348A (fr)
LT (1) LT2488551T (fr)
MA (1) MA33747B1 (fr)
MX (1) MX351635B (fr)
NI (1) NI201200054A (fr)
NZ (2) NZ599971A (fr)
PE (1) PE20121649A1 (fr)
PL (2) PL2488551T3 (fr)
PT (1) PT2488551T (fr)
RS (1) RS57966B1 (fr)
SG (1) SG10201704933PA (fr)
SI (1) SI2488551T1 (fr)
TN (1) TN2012000159A1 (fr)
TW (1) TWI537002B (fr)
UA (1) UA106771C2 (fr)
WO (1) WO2011045080A2 (fr)
ZA (1) ZA201202642B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (fr) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Compositions immunogènes comprenant de la progastrine, et utilisations de celles-ci
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
WO2011045080A2 (fr) * 2009-10-16 2011-04-21 Biorealites S.A.S. Anticorps monoclonaux contre la progastrine et leurs utilisations
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
NZ602992A (en) * 2010-03-24 2014-11-28 Servier Lab Prophylaxis of colorectal and gastrointestinal cancer
EP2598531B1 (fr) * 2010-07-26 2020-12-30 Progastrine et Cancers S.à r.l. Méthodes et compositions pour une thérapie contre le cancer du foie
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (fr) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour prédire le risque de développer une néoplasie du côlon
EP3016683B1 (fr) 2013-07-05 2020-06-24 University of Washington through its Center for Commercialization Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
EP3797793A1 (fr) * 2014-04-18 2021-03-31 The Research Foundation of the State University of New York at Buffalo Anticorps humanisés anti-antigène tf
WO2016066671A1 (fr) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour traiter des cancers résistants à l'aide d'inhibiteurs de la progastrine
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
TN2018000197A1 (en) * 2015-12-31 2019-10-04 Syncerus S A R L Compositions and methods for assessing the risk of cancer occurrence
WO2017114972A1 (fr) * 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions et méthodes pour dépister et traiter le cancer de l'ovaire
SG11201805141QA (en) * 2015-12-31 2018-07-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating gastric cancer
JP7071994B2 (ja) * 2017-03-30 2022-05-19 プロガストリン、エ、カンセル、エス、アー エル、エル 前立腺がんを治療するための組成物および方法
ES2926532T3 (es) * 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Composiciones y métodos para tratar el cáncer de pulmón
JP7104153B2 (ja) * 2017-12-05 2022-07-20 プロガストリン、エ、カンセル、エス、アー エル、エル 癌を治療するための抗プロガストリン抗体と免疫療法の併用療法
CA3085067A1 (fr) 2017-12-08 2019-06-13 Ecs-Biotracker Sarl Progastrine radiomarquee dans le diagnostic du cancer
WO2019145537A1 (fr) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combinaison de la détection de progastrine avec d'autres biomarqueurs du cancer dans le diagnostic du cancer
EP3759492A1 (fr) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrine en tant que biomarqueur pour l'immunothérapie
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
CN118126177A (zh) * 2023-11-22 2024-06-04 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO2006032980A1 (fr) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Anticorps monoclonaux de progastrine
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂
WO2008076454A1 (fr) * 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Compositions immunogènes comprenant de la progastrine, et utilisations de celles-ci
EP2337795A2 (fr) * 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
WO2011045080A2 (fr) * 2009-10-16 2011-04-21 Biorealites S.A.S. Anticorps monoclonaux contre la progastrine et leurs utilisations
NZ602992A (en) * 2010-03-24 2014-11-28 Servier Lab Prophylaxis of colorectal and gastrointestinal cancer

Also Published As

Publication number Publication date
CL2012000914A1 (es) 2012-09-14
US20170306011A1 (en) 2017-10-26
TWI537002B (zh) 2016-06-11
US20200002413A1 (en) 2020-01-02
CU24196B1 (es) 2016-09-30
ZA201202642B (en) 2013-06-26
TW201119675A (en) 2011-06-16
HRP20181645T1 (hr) 2018-12-14
EA029271B1 (ru) 2018-03-30
CN104628857A (zh) 2015-05-20
MX2012004400A (es) 2012-06-27
JP5985987B2 (ja) 2016-09-06
EP3421493C0 (fr) 2024-01-17
US20220195035A1 (en) 2022-06-23
JP2015145380A (ja) 2015-08-13
CA2777691A1 (fr) 2011-04-21
MX351635B (es) 2017-10-23
RS57966B1 (sr) 2019-01-31
IL254004B2 (en) 2023-06-01
JP2017212992A (ja) 2017-12-07
US10377821B2 (en) 2019-08-13
CN102791735A (zh) 2012-11-21
PT2488551T (pt) 2018-10-31
AP2012006262A0 (en) 2012-06-30
EP2488551A2 (fr) 2012-08-22
JP2013507138A (ja) 2013-03-04
BR112012008818B1 (pt) 2021-10-19
PE20121649A1 (es) 2012-12-08
CA2777691C (fr) 2018-02-27
IL219019A0 (en) 2012-06-28
JP6272793B2 (ja) 2018-01-31
EA201791876A1 (ru) 2018-01-31
ES2690943T3 (es) 2018-11-23
GEP201706604B (en) 2017-01-25
ECSP12011796A (es) 2012-06-29
US20110117086A1 (en) 2011-05-19
NZ599971A (en) 2014-12-24
NI201200054A (es) 2012-08-20
HN2012000708A (es) 2015-06-22
KR20120091221A (ko) 2012-08-17
EP3421493A1 (fr) 2019-01-02
US10385124B2 (en) 2019-08-20
SI2488551T1 (sl) 2019-01-31
PL2488551T3 (pl) 2019-01-31
SG10201704933PA (en) 2017-07-28
NZ701709A (en) 2016-06-24
EP2488551B1 (fr) 2018-07-25
GT201200114A (es) 2014-08-11
LT2488551T (lt) 2018-10-25
EP3421493B1 (fr) 2024-01-17
IN2012DN03348A (fr) 2015-10-23
HK1178183A1 (zh) 2013-09-06
PL3421493T3 (pl) 2024-04-29
US10385125B2 (en) 2019-08-20
US11299542B2 (en) 2022-04-12
EA201200597A1 (ru) 2012-12-28
WO2011045080A3 (fr) 2011-07-07
AU2010306119A1 (en) 2012-05-03
IL219019B (en) 2019-05-30
US20180022802A1 (en) 2018-01-25
WO2011045080A2 (fr) 2011-04-21
US20170306012A1 (en) 2017-10-26
ES2973217T3 (es) 2024-06-19
US20170174761A1 (en) 2017-06-22
US9611320B2 (en) 2017-04-04
KR101640520B1 (ko) 2016-07-19
CR20120184A (es) 2012-08-20
KR20150082672A (ko) 2015-07-15
IL254004A0 (en) 2017-10-31
US10385126B2 (en) 2019-08-20
CU20120060A7 (es) 2013-04-19
CY1120913T1 (el) 2019-12-11
UA106771C2 (uk) 2014-10-10
BR112012008818A2 (pt) 2018-05-22
TN2012000159A1 (en) 2013-12-12
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
DK2488551T3 (en) 2018-10-08

Similar Documents

Publication Publication Date Title
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
EP4357783A3 (fr) Système et procédés hautement sensibles pour l'analyse de troponine
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2007035651A3 (fr) Bio-essai de diagnostic du lupus erythemateux systemique
WO2010027903A8 (fr) Diagnostic du cancer du poumon
WO2011015602A3 (fr) Biomarqueurs du cancer du poumon
WO2011047033A3 (fr) Biomarqueur d'identification de cellules tumorales de mélanome
EP1934377A4 (fr) Procédés et compositions permettant d'identifier des biomarqueurs utiles au diagnostic et/ou au traitement d'états biologiques
WO2009090553A3 (fr) Compositions et procédés de détection de peptides post-arrêts
DK2129391T3 (da) Diagnostisk fremgangsmåde
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
WO2007084397A3 (fr) Méthode de traitement de slpi par chymase
MX2009010751A (es) Composiciones y metodos de deteccion.
EP2596121A4 (fr) Procédé pour relier des résultats d'analyses diagnostiques rapides au point d'intervention à des procédés en laboratoire
WO2010031749A9 (fr) Compositions et procédés pour détecter tlr3
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2010044506A3 (fr) Anticorps humain spécifique de tmprss4
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
GB2465907A (en) VHZ for diagnosis and treatment of cancer
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2007019276A3 (fr) Detection quantitative de plomb dans de l'eau
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MA30565B1 (fr) Procede de diagnostic et traitement anticancereux